The drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting targets ...

By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro ...

Mastercard, AstraZeneca and Sandisk face distinct opportunities and risks, from payment competition and drug pipeline growth ...

AstraZeneca (AZN) signed a drug-discovery deal with AI biotech insitro on Thursday, October 15, aimed at MASH, a serious liver disease, and cardiomyopathies, a group of heart-muscle diseases. The ...

AstraZeneca is paying insitro $40 million upfront to find novel drug targets for liver and heart diseases using artificial ...

AstraZeneca partners with insitro, investing up to $1.5 billion, to leverage the Virtual Human AI platform in developing ...

AstraZeneca Plc is collaborating with machine learning biotech Insitro Inc. in a deal worth as much as $1.86 billion intended ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant ...

Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.

The investment is expected to increase the pharma giant's workforce in Massachusetts to 3,000 employees within a few years.

Sept 28 (Reuters) - Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments ...

AstraZeneca has partnered with AI biotech insitro to identify drug targets and develop potential treatments for MASH, a ...